drugset / Trial / NCT04806581
Clinical Study of Hepatocyte Transplantation for Liver Cirrhosis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The Primary Objective: To observe and determine the safety and tolerance of allogeneic hepatocyte transplantation in patients with liver cirrhosis and to establish the maximum-tolerated dose (MTD) and evaluate the dose-limiting toxicities (DLTs). The Secondary Objective: To observe the therapeutic efficacy of allogeneic hepatocyte transplantation for liver cirrhosis.
Timeline
- Start
- 2021-04-20
- Primary completion
- 2024-12-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic Hepatocyte | Cell therapy | — | — |